Shots:
- VarmX has collaborated with CSL to advance its lead asset, VMX-C001 (commercial launch expected in 2029), & granted CSL an exclusive option agreement with its shareholders to acquire all issued & outstanding shares of the company
- As per the collaboration, CSL will fully fund the global P-III (EquilibriX-S) trial of VMX-C001 in FXa DOAC pts requiring urgent surgery, & support late-stage development, manufacturing, & pre-launch commercial & medical activities
- As per the deal, VarmX shareholders will receive $117M upfront for an exclusive option to acquire the company, exercisable upon P-III trial data, with ~$388M tied to acquisition & additional payments up to the commercial launch, plus ~1.7B in sales-based milestones
Ref: VarmX| Image: CSL and VarmX | Press Release
Related News:- CSL Receives Health Canada’s Approval for Andembry as a Prophylactic Treatment of Hereditary Angioedema (HAE)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
